Brasil | Artículos de revistas

Bosutinib Versus Imatinib In Newly Diagnosed Chronic-phase Chronic Myeloid Leukaemia: Results From The 24-month Follow-up Of The Bela Trial

dc.creatorBruemmendorf
dc.creatorTim H.; Cortes
dc.creatorJorge E.; de Souza
dc.creatorCarmino Antonio; Guilhot
dc.creatorFrancois; Duvillie
dc.creatorLadan; Pavlov
dc.creatorDmitri; Gogat
dc.creatorKarin; Countouriotis
dc.creatorAthena M.; Gambacorti-Passerini
dc.creatorCarlo
dc.date2015-JAN
dc.date2016-06-07T13:14:10Z
dc.date2016-06-07T13:14:10Z
dc.date.accessioned2018-03-29T01:34:58Z
dc.date.available2018-03-29T01:34:58Z
dc.identifier
dc.identifierBosutinib Versus Imatinib In Newly Diagnosed Chronic-phase Chronic Myeloid Leukaemia: Results From The 24-month Follow-up Of The Bela Trial. Wiley-blackwell, v. 168, p. 69-81 JAN-2015.
dc.identifier0007-1048
dc.identifierWOS:000346151600010
dc.identifier10.1111/bjh.13108
dc.identifierhttp://onlinelibrary.wiley.com/doi/10.1111/bjh.13108/abstract
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/241577
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1305275
dc.descriptionBosutinib is an oral, dual SRC/ABL1 tyrosine kinase inhibitor for resistant/intolerant chronic myeloid leukaemia (CML). We assessed the efficacy and safety of bosutinib 500mg/d (n=250) versus imatinib 400mg/d (n=252) after >24months from accrual completion in newly diagnosed chronic phase (CP)-CML (Bosutinib Efficacy and Safety in Newly Diagnosed CML trial [BELA]). Cumulative complete cytogenetic response (CCyR) rates by 24 months were similar (bosutinib, 79%; imatinib, 80%); cumulative major molecular response (MMR) rates were 59% for bosutinib and 49% for imatinib. Responses were durable; 151/197 vs. 172/204 and 125/153 vs. 117/131 responders remained on treatment and maintained CCyR and MMR, respectively. Since the 12-month primary analysis, no new accelerated-/blast-phase transformations occurred with bosutinib; four occurred with imatinib. Early response (BCR-ABL1/ABL110%, 3months) was associated with better CCyR and MMR rates by 12 and 24months (both arms). Gastrointestinal events and liver function test elevations were more common, and neutropenia, musculoskeletal events and oedema were less common with bosutinib. Discontinuations due to adverse events were more common with bosutinib versus imatinib (most commonly alanine aminotransferase elevation: 4% vs. <1%); most occurred within the first 12months. Cardiovascular adverse events were similar in both arms. Bosutinib continues to demonstrate good efficacy and manageable tolerability in newly diagnosed CP-CML patients.
dc.description168
dc.description1
dc.description
dc.description69
dc.description81
dc.descriptionWyeth Research
dc.descriptionPfizer
dc.description
dc.description
dc.description
dc.languageen
dc.publisherWILEY-BLACKWELL
dc.publisher
dc.publisherHOBOKEN
dc.relationBRITISH JOURNAL OF HAEMATOLOGY
dc.rightsfechado
dc.sourceWOS
dc.subjectChronic Myelogenous Leukemia
dc.subjectPatients Receiving Imatinib
dc.subjectCytogenetic Responses
dc.subjectMolecular Responses
dc.subjectInterferon-alpha
dc.subjectIn-vitro
dc.subjectDasatinib
dc.subjectResistant
dc.subjectNilotinib
dc.subjectInhibitor
dc.titleBosutinib Versus Imatinib In Newly Diagnosed Chronic-phase Chronic Myeloid Leukaemia: Results From The 24-month Follow-up Of The Bela Trial
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución